0C-07-9, PH1-60 A PHASE 1 AND PHARMACOKINETIC SINGLE AGENT STUDY OF PAZOPANIB

0C-07-9，PH1-60 A 1 期和帕唑帕尼单药药代动力学研究

• 批准号: 7982144
• 负责人: HEINZ JOSEF LENZ
• 金额: $ 0.93万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982144
• 关键词: Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Drug Kinetics; Functional disorder; Funding; Grant; Hepatic; Institution; Patients; Phase; Phase I Clinical Trials; Research; Research Personnel; Resources; Sampling; Source; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center, Phase 1 trial to establish MTD of pazopanib in groups ot patients with varying degrees of hepatic dysfunction. This iral agent will be given daily. Pharmacokinetic samples will be done on cycle 1 , day 14 in the escalation phase and on day 1, week 3 in the expansion phase.PD profiles of pazopanib and it metaboites will also be done. Antitumor activity wil also be assessed.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是一项多中心的第1阶段试验，可在不同程度的肝功能障碍的患者组中建立Pazopanib的MTD。这个iral代理人每天都会给予。药代动力学样本将在升级阶段的第14天，第1天，在扩展阶段的第1周完成。Pazopanib和IT代替伯特的PD轮廓也将完成。还将评估抗肿瘤活性。